Trials for neurodegenerative diseases: time to innovate

Arpan R Mehta, Jeremy Chataway, Suvankar Pal, Mahesh K B Parmar, Siddharthan Chandran

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The remarkable progress in our understanding of the mechanisms underlying neurodegenerative diseases heralds an era when neurologists would be at the vanguard of regenerative medicine, instead of chroniclers of decline. To capitalise on these advances that are identifying ever more therapeutic candidates, whether repurposed or entirely new, there is an urgent need for refined methods to test these putative medicines in clinical trials. Our field has the opportunity to learn from innovations in trial design, particularly those pioneered in oncology.
Original languageEnglish
Pages (from-to)984
Number of pages1
JournalLancet Neurology
Volume20
Issue number12
Early online date17 Nov 2021
DOIs
Publication statusPublished - Dec 2021

Fingerprint

Dive into the research topics of 'Trials for neurodegenerative diseases: time to innovate'. Together they form a unique fingerprint.

Cite this